Semaglutide and cardiovascular outcomes in obesity without diabetes

AM Lincoff, K Brown-Frandsen… - … England Journal of …, 2023 - Mass Medical Soc
… with Overweight or Obesity (SELECT) trial, we tested the hypothesis that the addition of
semaglutide … the risk of major adverse cardiovascular events among patients with overweight or …

[HTML][HTML] Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design

DH Ryan, I Lingvay, HM Colhoun, J Deanfield… - American heart …, 2020 - Elsevier
outcome and demonstrates reduced CVD events in persons with obesity and prior CVD
but without diabetes, semaglutide 2.4 mg once weekly treatment should inform obesity

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics

I Lingvay, K Brown‐Frandsen, HM Colhoun… - …, 2023 - Wiley Online Library
… administered dose of 2.4 mg semaglutide on CV outcomes compared with placebo in people
without diabetes but who were living with overweight or obesity and who suffered from a …

[HTML][HTML] Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: a systematic review and meta-analysis of randomized …

X Gao, X Hua, X Wang, W Xu, Y Zhang… - Frontiers in …, 2022 -
… elaborated potentially beneficial effects on cardiovascular … beyond weight reduction in obese
people without diabetes. … studies about semaglutide treating obesity without diabetes, one …

[HTML][HTML] Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes

M Husain, AL Birkenfeld, M Donsmark… - … England Journal of …, 2019 - Mass Medical Soc
… We assessed cardiovascular outcomes of once-daily oral semaglutide in an event-driven,
randomized, double-blind, placebo-controlled trial involving patients at high cardiovascular

[HTML][HTML] US population eligibility and estimated impact of Semaglutide treatment on obesity prevalence and cardiovascular Disease events

ND Wong, H Karthikeyan, W Fan - Cardiovascular Drugs and Therapy, 2023 - Springer
… healthcare costs associated with obesity and CVD. The ongoing … of semaglutide treatment
on cardiovascular outcomes in high-risk adults and established CVD and without diabetes. …

Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review

Y Deng, A Park, L Zhu, W Xie… - Therapeutic Advances in …, 2022 -
… with diabetes. While few reviews focused on obese/overweight individuals without diabetes,
we aimed to perform a systematic review of semaglutide and liraglutide in randomized …

Cardiovascular outcome trials in obesity: a review

JPH Wilding, S Jacob - Obesity reviews, 2021 - Wiley Online Library
… liraglutide and semaglutide improved CV and renal outcomes with no apparent
differences across BMI groups. However, subgroup analysis of the EMPA-REG OUTCOME (empagliflozin…

Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses

MN Kosiborod, M Bhatta, M Davies… - Diabetes, Obesity …, 2023 - Wiley Online Library
… or CV outcomes in people with overweight/obesity without T2D. The effects of semaglutide
on … 3, a trial in people with overweight/obesity without T2D with a broadly similar design to …

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

M Husain, SC Bain, OK Jeppesen… - Diabetes, Obesity …, 2020 - Wiley Online Library
Cardiovascular (CV) disease (CVD) is the leading cause of morbidity and mortality in patients
with type 2 diabetes (T2D).1 CV outcomes trials (CVOTs) have demonstrated the CV safety …